Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease

Abstract

Flavopiridol achieves significant clinical activity in patients with relapsed CLL, including those with high-risk genomic features and bulky lymphadenopathy. Subsequent clinical trials should use the amended treatment schedule developed herein and prophylactic corticosteroids.

References

Page 1

	Year	Citations
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment Cheson Bd, J M Bennett, Michael R. Grever, Blood	1996	1.8K
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia Michael J. Keating, Susan O’Brien, Maher Albitar, Journal of Clinical Oncology	2005	947
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study Michael J. Keating, Ian W. Flinn, Vinay Jain, Blood	2002	946
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias H. Döhner, Konstanze Fischer, Martin Bentz, Blood	1995	732
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial Daniel Catovsky, Estella Matutes, R. F. Bezares, The Lancet Hematological MalignancyLymphoid NeoplasiaOncologyChronic Lymphocytic LeukaemiaMedicine	2007	678
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial Patrick J. Loehrer Yearbook of Oncology Hematological MalignancyLymphoid NeoplasiaOncologyChronic Lymphocytic LeukaemiaMedicine	2008	602
Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Bradley A. Carlson, M M Dubay, Edward A. Sausville, PubMed Breast OncologyChemoprevention StrategyCancer BiologyTumor BiologyCdk4 Kinase Activity	1996	537
Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity John C. Byrd, Timothy J. Murphy, Robin Howard, Journal of Clinical Oncology	2001	511
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions Gerard Lozanski, Nyla A. Heerema, Ian W. Flinn, Blood	2004	403
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia John C. Byrd, Thomas S. Lin, James T. Dalton, Blood	2006	387

Page 1